CN102014898B - 用于减少尿酸的四唑化合物 - Google Patents

用于减少尿酸的四唑化合物 Download PDF

Info

Publication number
CN102014898B
CN102014898B CN2009801155473A CN200980115547A CN102014898B CN 102014898 B CN102014898 B CN 102014898B CN 2009801155473 A CN2009801155473 A CN 2009801155473A CN 200980115547 A CN200980115547 A CN 200980115547A CN 102014898 B CN102014898 B CN 102014898B
Authority
CN
China
Prior art keywords
compound
group
carbon atoms
uric acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801155473A
Other languages
English (en)
Chinese (zh)
Other versions
CN102014898A (zh
Inventor
詹姆斯·邓恩·奥尼尔
沙林·夏尔马
拉马钱德兰·阿鲁德钱德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Therapeutics Corp
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Publication of CN102014898A publication Critical patent/CN102014898A/zh
Application granted granted Critical
Publication of CN102014898B publication Critical patent/CN102014898B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801155473A 2008-04-30 2009-04-30 用于减少尿酸的四唑化合物 Expired - Fee Related CN102014898B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4916708P 2008-04-30 2008-04-30
US61/049,167 2008-04-30
US9374308P 2008-09-03 2008-09-03
US61/093,743 2008-09-03
PCT/US2009/042298 WO2009134995A2 (en) 2008-04-30 2009-04-30 Tetrazole compounds for reducing uric acid

Publications (2)

Publication Number Publication Date
CN102014898A CN102014898A (zh) 2011-04-13
CN102014898B true CN102014898B (zh) 2013-01-23

Family

ID=41255799

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801155473A Expired - Fee Related CN102014898B (zh) 2008-04-30 2009-04-30 用于减少尿酸的四唑化合物

Country Status (15)

Country Link
US (2) US8410154B2 (enExample)
EP (1) EP2282736B1 (enExample)
JP (1) JP5431457B2 (enExample)
KR (1) KR101613611B1 (enExample)
CN (1) CN102014898B (enExample)
AU (1) AU2009243028B2 (enExample)
BR (1) BRPI0910541B8 (enExample)
CA (1) CA2722624C (enExample)
ES (1) ES2561039T3 (enExample)
IL (1) IL209004A (enExample)
MX (1) MX2010011603A (enExample)
NZ (1) NZ588374A (enExample)
RU (1) RU2522458C2 (enExample)
WO (1) WO2009134995A2 (enExample)
ZA (1) ZA201006929B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716860C (en) 2008-03-13 2017-08-29 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
CN102014898B (zh) 2008-04-30 2013-01-23 维尔斯达医疗公司 用于减少尿酸的四唑化合物
JP5806221B2 (ja) * 2009-10-13 2015-11-10 ウェルスタット セラピューティクス コーポレイション 尿酸を減少させる３−置換化合物
WO2012033720A1 (en) * 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
PL2776028T3 (pl) * 2011-11-03 2019-03-29 Ardea Biosciences, Inc. 3,4-di-podstawiony związek pirydynowy, sposoby jego zastosowania i zawierające go kompozycje
DK2775836T3 (en) * 2011-11-04 2018-12-03 Cymabay Therapeutics Inc PROCEDURES FOR TREATING GIG RETURN
TW201334779A (zh) * 2012-01-27 2013-09-01 Teijin Pharma Ltd 糖尿病的治療藥
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
CN104292176B (zh) * 2014-10-07 2016-06-29 张远强 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途
CN104292177B (zh) * 2014-10-07 2016-08-17 张远强 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104262277B (zh) * 2014-10-07 2016-06-22 张远强 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
RU2683570C1 (ru) * 2018-05-23 2019-03-29 Евгений Иванович Верещагин Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
US4024253A (en) 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US4182764A (en) 1973-10-11 1980-01-08 Merck & Co., Inc. Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids
US4874777A (en) 1987-04-10 1989-10-17 Eli Lilly And Company Leukotriene antagonists
US4845231A (en) 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
FR2631827B1 (fr) 1988-05-27 1992-03-27 Delalande Sa Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
CA2245529A1 (en) 1996-02-02 1997-08-07 Soumya P. Sahoo Antidiabetic agents
PL344977A1 (en) 1997-10-17 2001-11-19 Aventis Pharm Prod Inc Therapeutic uses of quinoline derivatives
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
CN100344616C (zh) 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
AU2003226094A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
JP2004197711A (ja) * 2002-12-20 2004-07-15 Honda Motor Co Ltd 回転流体機械
MXPA05009565A (es) * 2003-03-11 2005-12-02 Novo Nordisk As Preparaciones farmaceuticas que comprenden insulina estabilizada con acido.
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
CA2716860C (en) 2008-03-13 2017-08-29 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
CN102014898B (zh) 2008-04-30 2013-01-23 维尔斯达医疗公司 用于减少尿酸的四唑化合物

Also Published As

Publication number Publication date
CN102014898A (zh) 2011-04-13
KR20100135851A (ko) 2010-12-27
KR101613611B1 (ko) 2016-04-19
IL209004A (en) 2014-04-30
JP5431457B2 (ja) 2014-03-05
NZ588374A (en) 2012-11-30
AU2009243028A1 (en) 2009-11-05
US8410154B2 (en) 2013-04-02
RU2522458C2 (ru) 2014-07-10
AU2009243028B2 (en) 2015-01-29
BRPI0910541B1 (pt) 2019-12-03
EP2282736A4 (en) 2011-06-15
CA2722624A1 (en) 2009-11-05
CA2722624C (en) 2017-03-21
JP2011519865A (ja) 2011-07-14
BRPI0910541B8 (pt) 2021-05-25
ZA201006929B (en) 2011-06-29
EP2282736B1 (en) 2015-11-11
US20110206653A1 (en) 2011-08-25
MX2010011603A (es) 2011-01-25
RU2010148762A (ru) 2012-06-10
WO2009134995A3 (en) 2009-12-23
US8889724B2 (en) 2014-11-18
IL209004A0 (en) 2011-01-31
US20130336949A1 (en) 2013-12-19
WO2009134995A2 (en) 2009-11-05
ES2561039T3 (es) 2016-02-24
HK1147446A1 (en) 2011-08-12
EP2282736A2 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
CN102014898B (zh) 用于减少尿酸的四唑化合物
US9115072B2 (en) Compounds and method for reducing uric acid
US10085957B2 (en) Benzoic acid compounds for reducing uric acid
US20140142185A1 (en) 3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
HK1147446B (en) Tetrazole compounds for reducing uric acid
HK40011494A (en) Compounds and method for reducing uric acid
HK1147647B (en) Compounds and method for reducing uric acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130123

CF01 Termination of patent right due to non-payment of annual fee